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Abstract
Background: A recent genome-wide association study in German Shepherd dogs
(GSDs) with chronic enteropathy (CE) has identified polymorphisms in the Th2 cyto-
kine genes.
Hypothesis/objective: To determine if the expression of the Th2 cytokines, interleukin-
13 (IL-13) and interleukin-33 (IL-33), is altered in the duodenal mucosa of GSDs with CE
compared to non-GSDs with CE and healthy dogs.
Animals: Twenty client-owned dogs diagnosed with CE (10 GSDs and 10 non-GSDs)
at the Bristol Veterinary School and 8 healthy Beagle dogs from the Iowa State
University Service Colony.
Methods: Retrospective study using archived paraffin-embedded duodenal biopsy
samples. A novel RNA in situ hybridization technology (RNAscope) was used to
hybridize IL-13 and IL-33 mRNA probes onto at least 10 sections from duodenal
biopsy samples for each dog. RNAscope signals were visualized using a microscope
and semi-quantitative assessment was performed by a single operator.
Results: Based on duodenal villus, subvillus, epithelial, and lamina propria average
expression scores, GSDs with CE had significantly lower IL-13 and IL-33 mRNA
expression compared to non-GSDs with CE (IL-13, P < .04; IL-33, P < .02) and healthy
Beagle dogs (IL-13, P < .02; IL-33, P < .004).
Conclusions and Clinical Importance: Similar to human patients with ulcerative coli-
tis, a subtype of human inflammatory bowel disease, these data indicate that Th2
cytokines may be involved in the pathogenesis of CE in GSDs.
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1 | INTRODUCTION
Inflammatory bowel disease (IBD) in humans is an idiopathic chronic
relapsing disease,1 hypothesized to involve the interplay of 4 key
components: (1) genetic susceptibility, (2) environmental risk factors,
(3) intestinal dysbiosis, and (4) altered gastrointestinal (GI) mucosal
immune response.2 Inflammatory bowel disease in humans is com-
prised of Crohn's disease (CD) and ulcerative colitis (UC), which differ
in pathogenesis, localization of disease within the GI tract, and thera-
peutic management.2 The identification of inflammatory mediators
by genome-wide association studies (GWAS) has enabled the develop-
ment of specific treatment options for either CD or UC, with efficacious
biologic drugs such as infliximab (anti tumor necrosis factor-alpha
antibody) in CD3-5 and tofacitinib6,7 (a JAK kinase inhibitor that
decreases secretion of several Th2 cytokines) in UC.
Similar to IBD in humans, chronic enteropathy (CE) in dogs also is
a chronic relapsing disease and the pathogenesis is considered to
involve the same 4 key components.8 Chronic enteropathy is predom-
inantly treated with corticosteroids,9,10 but up to 50% of dogs will
develop resistance, clinically important adverse effects, or both, which
ultimately leads to euthanasia.11 It is therefore critical to develop
more specific and efficacious treatment for long-term management of
dogs with CE. In the United Kingdom, German Shepherd dogs (GSDs)
are at a significantly higher risk of developing CE compared with
mixed breed dogs.12 One recent study identified several single nucleo-
tide polymorphisms in IL-4, IL-5, and IL-13 that were significantly
associated with CE in GSDs.13 This novel finding is reminiscent of the
strong Th2 cytokine predominance found in the intestinal mucosa in
humans with UC and suggests that Th2 cytokines also might be impli-
cated in the pathogenesis of CE in GSDs. Previous studies investigat-
ing the mucosal cytokine profile in dogs with CE have not definitively
determined a Th1, Th2, or Th17 predominance.14,15 However, many
of these studies were performed on few samples and utilized different
molecular methods, which makes it difficult to directly compare
results among studies. Also, these studies largely included different
breeds of dogs, and because of limited sample sizes, subanalysis of
cytokine expression for each breed was not performed. Inflammatory
profiles may differ among breeds of dogs presenting with CE, because
of different etiopathogeneses.
We aimed to determine if mRNA expression of the Th2 cytokines,
IL-13 and IL-33 was altered in the duodenal mucosa of GSDs with CE
compared to non-GSDs with CE and healthy Beagle dogs, using a novel
RNA in situ hybridization (ISH) technology, RNAscope. The advantages
of RNAscope include a unique patented probe (Z probe) design which
increases amplification of target-specific signals but not background
noise.16 Interleukin-13 and IL-33 were chosen for further investigation,
because recent results of GWAS in GSDs with CE implicated the IL-13
gene, and studies in human and mouse models of IBD have highlighted
the importance of IL-33, which has not been extensively investigated to
date in dogs with CE. We hoped to further unravel the pathogenesis of
CE in GSDs, which might help in the development of novel therapeutic
modalities, as is already the case for UC in humans.
2 | MATERIALS AND METHODS
2.1 | Study design
We performed a retrospective study using archived paraffin-embedded 10%
formalin-fixed duodenal biopsy samples from dogs with CE referred to Bris-
tol Veterinary School. Tissue specimens from 3 groups of dogs were studied:
GSD CE (N = 10), non-GSD CE (N = 10), and healthy controls (N = 8) from a
population of healthy Beagle dogs at the Iowa State University.
2.2 | Retrospective study criteria for case selection
The histopathology archive at the Bristol Veterinary School was searched
for GSD and non-GSD cases with a histologic diagnosis of chronic inflam-
matory enteropathy. All medical records were then reviewed by 1 of the
authors (Aarti Kathrani). Only dogs with a histologic diagnosis of chronic
inflammatory enteropathy that had adequate and appropriate investiga-
tions to exclude other causes of chronic GI signs before histologic diagno-
sis were included.17 All dogs had intestinal biopsy samples collected during
endoscopy. Complete blood count, serum biochemistry profile, serum
cobalamin and folate concentrations, tests for pancreatic disease (canine
pancreatic lipase immunoreactivity and trypsin-like immunoreactivity),
basal serum cortisol concentration, preprandial and postprandial serum
bile acid concentrations, fecal parasitology using saturated zinc sulfate flo-
tation, fecal culture (for Salmonella,Campylobacter, andClostridium difficile),
and abdominal ultrasound examination or computed tomography were
performed in most dogs, as indicated by the history and physical
examination.
The canine chronic enteropathy activity index (CCEAI),10 which is
based on the presence and severity of 9 factors, including attitude or
activity, appetite, vomiting, fecal consistency, frequency of defeca-
tion, weight loss, serum albumin concentration, ascites, and peripheral
edema and pruritus, was retrospectively calculated for each dog based
on the history collected at admission and the referring veterinarian's
medical records.
Archived paraffin-embedded duodenal biopsy samples were retrieved
from the archive at Bristol Veterinary School for the selected cases, and
at least 10 sections, mounted onto glass slides from each dog, were sent
to Iowa State University for IL-13 and IL-33 RNA ISH.
2.3 | Control dogs
The research colony at the Iowa State University (8 female spayed Bea-
gle dogs, 2 years of age) was used to obtain intestinal biopsy samples
from healthy control dogs. The dogs were assessed as clinically healthy,
and had a CBC, serum biochemistry profile, urinalysis, and fecal parasi-
tology performed, all of which were normal. Duodenal biopsy samples
were collected from control dogs during upper GI endoscopy.
2.4 | RNA in situ hybridization
The technique of RNA ISH allows detection of specific RNA
sequences with cellular resolution within tissue architecture on
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routine formalin-fixed paraffin-embedded tissue specimens. We used
a novel RNA ISH technology, RNAscope (ACD Biotech, Newark,
California), which provides single-molecule visualization while pre-
serving tissue morphology.16 Two slides with ≥5 duodenal biopsy
samples per dog were hybridized with specially patented probes
with oligonucleotide bases. These unique patented probes were
specifically designed against the canine genetic sequences of IL-13
and IL-33 and verified by the manufacturer (ACD Bio Techne). Slides
then were examined and positive controls were included for each
hybridization using ubiquitin C. Preparation and hybridization of the
slides were done in accordance with the user manual's protocol pro-
vided by ACD Biotech and using RNAscope 2.5 HD Assay—RED.16
2.5 | Visualization and image capture
The RNAscope signals were visualized by using a 20X Plan N lens on
an Olympus BX40 microscope (Olympus Optical Co, Ltd, Tokyo,
Japan) and photographed with an Olympus DP27 camera (Olympus
Optical Co, Ltd). Ten images were obtained from different representa-
tive fields per slide. A representative mucosal field was defined as
containing ≥3 duodenal biopsy samples containing ≥3 contiguous villi
for diagnostic evaluation.18
2.6 | Semi-quantitative analysis of mRNA expression
Semi-quantitative image analysis was performed using Fiji ImageJ on
in situ hybridized slides using RNAscope assay according to ACD Bio
Techne instructions. Semi-quantitative image analysis was performed
on 6 sections from each case and expressed as positive dots per cell
over the total percentage area of cells by a single operator (Victor
Lezcano) in a nonblinded fashion. The Semi-quantitative assessment
consisted of an estimated total count of cells expressing signal in each
representative field. Mucosal fields then were evaluated for cell distri-
bution in different regions of the duodenal mucosa. The spatial distri-
bution of expression was defined as: (1) villus in location; (2) subvillus
in location; (3) within intestinal epithelium; and (4) within the lamina
propria. A histologic grading score of 0-3 was used to define cell num-
bers where 0 = none; 1 = minimum expression; 2 = moderate expres-
sion; and 3 = exaggerated expression.
2.7 | Ethical considerations
Archived paraffin-embedded duodenal biopsy samples were used
and the University of Bristol granted ethical approval for the study
(VIN/18/014). Iowa State University granted ethical approval for
the use of paraffin-embedded duodenal biopsy samples from healthy
colony Beagle dogs (9-17-8605-K).
2.8 | Data analysis and statistics
The Shapiro-Wilk and Levene's tests were used to assess the assump-
tions of normality and homoscedasticity, respectively. A 1-way analy-
sis of variance (ANOVA) was performed to assess for any significant
differences in average mRNA expression scores of IL-13 and IL-33 in
the different mucosal compartments (villus, subvillus, epithelial, and
lamina propria) among the 3 groups (GSD CE, non-GSD CE, and
healthy). Post hoc pairwise comparisons then were performed using
Tukey's honest significant difference test. Significance was defined as
P < .05. Statistical analyses were performed using IBM SPSS Statistics
version 24 and R Statistical software, version 3.5.1.
3 | RESULTS
3.1 | Dogs
Ten GSDs with CE were included in the study: 5 female neutered and
5 male neutered dogs, with a median age of 7.2 years and a range of
1.6 to 10 years. The median CCEAI score was 9 with a range of 4 to
13. Six dogs were diagnosed with eosinophilic enteritis and 1 with
each of the following: lymphoplasmacytic enteritis, lymphoplasmacytic
and eosinophilic enteritis, eosinophilic and neutrophilic enteritis, and
lymphoplasmacytic, eosinophilic, and neutrophilic enteritis. One dog
had protein-losing enteropathy as a consequence of its CE, another
had exocrine pancreatic insufficiency, and another had an incidental
gastric foreign body.
Ten non-GSDs with CE were included in the study: 2 Border Col-
lies, 2 Boxers, and 1 each of the following breeds: West Highland
White Terrier, Beagle, Siberian Husky, Chihuahua, Border Terrier, and
Cavalier King Charles Spaniel. There were 6 female neutered, 3 male
neutered, and 1 male intact dog, with a median age of 7.9 years and a
range of 0.8 to 11 years. The median CCEAI score was 6.5 with a
range of 3 to 11. Three dogs were diagnosed with eosinophilic enteri-
tis, 2 dogs with lymphoplasmacytic, neutrophilic, and eosinophilic
enteritis, 2 dogs with lymphoplasmacytic and eosinophilic enteritis,
and 1 with each of the following: lymphoplasmacytic enteritis, lym-
phocytic enteritis, and plasmacytic enteritis. One dog had concurrent
chronic partial gastric torsion. Ten healthy Beagle control dogs were
included; all were female spayed and 2 years of age.
There were no significant differences in age or CCEAI between
the GSD CE and non-GSD CE groups (P > .22).
3.2 | Interleukin-13 mRNA
One-way ANOVA comparing IL-13 mRNA duodenal villus, subvillus,
epithelial, and lamina propria average expression scores among GSDs
with CE, non-GSDs with CE, and healthy dogs showed a significant
difference for all 4 distribution scores among the 3 groups (P < .03).
Post hoc analysis using the Tukey's Honest Significant Difference
test showed that GSDs with CE had significantly lower average IL-13
mRNA duodenal villus, subvillus, epithelial, and lamina propria expres-
sion scores compared to non-GSDs with CE (mean ± SD): (1) villus
score: GSD CE, 0.43 ± 0.30; non-GSD CE, 0.81 ± 0.37; P = .03; (2) sub-
villus score: GSD CE, 0.06 ± 0.11; non-GSD CE, 0.33 ± 0.26; P = .04;
(3) epithelial score: GSD CE, 0.07 ± 0.19; non-GSD CE, 0.44 ± 0.47;
P = .03; and (4) lamina propria score: GSD CE, 0.43 ± 0.31; non-GSD
CE, 0.82 ± 0.24; P = .009 (Table 1 and Figure 1).
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In addition, GSDs with CE had significantly lower duodenal subvillus
and lamina propria average expression scores compared to healthy con-
trol dogs: (1) subvillus score: GSD CE, 0.06 ± 0.11; healthy 0.40 ± 0.30;
P = .01 and (2) lamina propria score: GSD CE, 0.43 ± 0.31; healthy,
0.81 ± 0.25; P = .02 (Table 1; Figures 1 and 2).
Lastly, the post hoc analysis showed that non-GSDs with CE had
significantly higher IL-13 mRNA duodenal epithelial average expres-
sion score compared to healthy control dogs: non-GSD CE, 0.44 ± 0.47;
healthy, 0.05 ± 0.09; P = .03 (Table 1 and Figure 1).
3.3 | Interleukin-33 mRNA
One-way ANOVA comparing average IL-33 mRNA duodenal villus,
subvillus, epithelial, and lamina propria expression scores among GSDs
with CE, non-GSDs with CE, and healthy dogs showed a significant dif-
ference for subvillus, epithelial, and lamina propria expression scores
among the 3 groups (P < .01).
Post hoc analysis using Tukey's Honest Significant Difference test
showed that GSDs with CE had significantly lower average IL-33
mRNA duodenal subvillus, epithelial and lamina propria expression
scores compared to non-GSDs with CE and lower average subvillus
and epithelial expression scores compared to healthy control dogs:
GSD CE vs Non-GSD CE: (1) subvillus score: GSD CE, 0.37 ± 0.49; non-
GSD CE, 1.36 ± 0.49; P < .001; (2) epithelial score: GSD CE, 0.50 ± 0.83;
non-GSD CE, 1.58 ± 0.86; P = .01; (3) lamina propria score: GSD
CE, 0.73 ± 0.49; non-GSD CE, 1.35 ± 0.39; P = .007 (Table 2). For
GSD CE versus healthy: (1) subvillus score: GSD CE, 0.37 ± 0.49;
healthy, 1.37 ± 0.42; P < .001; (2) epithelial score: GSD CE, 0.50 ± 0.83;
healthy, 1.84 ± 0.53; P = .003 (Table 2; Figures 3 and 4). There were no
significant differences in IL-33 mRNA expression between non-GSDs
with CE and healthy control dogs (Table 2).
4 | DISCUSSION
Cytokines in the Th2 pathway have been implicated in the pathogene-
sis of UC, a subtype of IBD in humans.19 Similarly, a recent GWAS has
implicated the possible role of Th2 cytokines in the pathogenesis of
TABLE 1 Post hoc analysis of interleukin (IL)-13 mRNA duodenal villus, subvillus, epithelial, and lamina propria average expression scores in
German Shepherd dogs (GSDs) with chronic enteropathy (CE), non-GSDs with CE, and healthy Beagle control dogs using RNA in situ
hybridization. P-values obtained from post hoc analysis using Tukey's Honest Significant Difference test after 1-way analysis of variance testing
of IL-13 mRNA duodenal villus, subvillus, epithelial, and lamina propria average expression scores in GSDs with CE (N = 10), non-GSDs with CE
(N = 10), and healthy Beagle control dogs (N = 8)
Villus score Subvillus score Epithelial score Lamina propria score
GSD CE versus Non-GSD CE .03 .04 .03 .009
Healthy control .07 .01 .99 .02
Non-GSD CE versus Healthy control .96 .80 .03 .99
Significance was defined in bold as P < .05.
F IGURE 1 Individual scatter dot plot
showing interleukin (IL)-13 mRNA
duodenal villus, subvillus, epithelial, and
lamina propria average expression scores
for healthy Beagle control dogs (N = 8),
German Shepherd dogs (GSDs) with
chronic enteropathy (CE) (N = 10), and
non-GSDs with CE (N = 10). Line
represents mean with SD. There were
significant differences in IL-13 mRNA
duodenal villus, subvillus, epithelial, and
lamina propria average expression scores
between GSDs with CE and non-GSDs
with CE, P < .04. There also were
significant differences in IL-13 mRNA
duodenal subvillus and lamina propria
average expression scores between GSDs
with CE and healthy Beagle control dogs,
P < .02; and epithelial average expression
score between non-GSDs with CE and
healthy Beagle control dogs, P = .03
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CE in GSDs.13 Therefore, we aimed to determine whether the mRNA
expression of 2 Th2 cytokines, IL-13 and IL-33, was altered in the
duodenal mucosa of GSDs with CE compared to non-GSDs with CE
and healthy control dogs. Our study showed that GSDs with CE had
significantly decreased IL-13 and IL-33 mRNA expression in the duo-
denal mucosa compared with non-GSDs with CE and healthy dogs.
Interleukin-33 functions both as a cytokine and as a nuclear tran-
scription factor.20 It activates both the innate and adaptive immune
F IGURE 2 RNA in situ hybridization of interleukin (IL)-13 in the subvillus of the duodenal mucosa of a German Shepherd dog with chronic
enteropathy (left image) and a healthy Beagle control dog (right image). The central image depicts a negative control from a German Shepherd
dog with chronic enteropathy
TABLE 2 Post hoc analysis of interleukin (IL)-33 mRNA duodenal villus, subvillus, epithelial, and lamina propria average expression scores in
German Shepherd dogs (GSDs) with chronic enteropathy (CE), non-GSDs with CE and healthy Beagle control dogs using RNA in situ hybridization.
P-values obtained from post hoc analysis using Tukey's Honest Significant Difference test after 1-way analysis of variance testing of IL-33 mRNA
duodenal villus, subvillus, epithelial, and lamina propria average expression scores in GSDs with CE (N = 10), non-GSDs with CE (N = 10), and healthy
Beagle control dogs (N = 8)
Villus score Subvillus score Epithelial score Lamina propria score
GSD CE versus Non-GSD CE .08 <.001 .01 .007
Healthy control .16 <.001 .003 .13
Non-GSD CE versus Healthy control .96 .99 .76 .49
Significance was defined in bold as P < .05.
F IGURE 3 Individual scatter dot plot
showing interleukin (IL)-33 mRNA
duodenal villus, subvillus, epithelial, and
lamina propria average expression scores
in healthy Beagle control dogs (N = 8),
German Shepherd dogs (GSDs) with
chronic enteropathy (CE) (N = 10), and
non-GSDs with CE (N = 10). Line
represents mean with SD. There were
significant differences in IL-33 mRNA
duodenal subvillus, epithelial, and lamina
propria average expression scores
between GSDs with CE and non-GSDs
with CE, P < .02. There were also
significant differences in IL-33 mRNA
duodenal subvillus and epithelial average
expression scores between GSDs with CE
and healthy Beagle dogs, P < .004
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system and is a critical cytokine for Th2-mediated host defense, as
well as playing a key role in regulating immune responses in barrier tis-
sues such as the intestine.20,21 Interleukin-33 also functions as an ala-
rmin and is released by epithelial and endothelial cells in response to
cell injury and necrosis.20 Therefore, IL-33 acts as an important early
indicator for the immune system when a breach in mucosal barrier
function occurs.22 Also, because IL-33 promotes an early Th2 immune
response, it helps to regulate Th1 immune responses and prevent
autoimmunity.23,24 Interleukin-33 has been shown to influence both T
regulatory cells and Th17 cells to decrease inflammation and protect
the intestinal mucosa from self-inflicted injury.21 Studies suggest that
nuclear IL-33 can sequester nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB), thereby decreasing subsequent NF-κB-
generated proinflammatory signaling.25 Interleukin-33 also may be
involved in mucus production, because mice given exogenous IL-33
in vivo produce more colonic mucin.26 A recent study also suggests
a protective role for IL-33 in epithelial regeneration and intestinal
mucosal wound healing.27
The protective effects of IL-33 mainly have been demonstrated in
mouse models. Several studies have shown that IL-33 knockout mice
are more susceptible to dextran sodium sulfate (DSS) administration
compared to wild-type mice.28-30 Interleukin-33 treatment amelio-
rated colitis in DSS, 2,4,6-trinitrobenzenesulfonic acid, and peritoneal
cavity cell transfer models.31 Interleukin-33 treatment also increased
B and T regulatory cell responses, suppressed Th17 responses, and
switched Th1 to Th2 response in DSS-induced colitis.32,33 Interleukin-
33 has been shown to promote IgA production by B cells, which is
important for maintaining intestinal homeostasis.28 Interleukin-33 defi-
cient mice also developed intestinal dysbiosis, which was characterized
by increased numbers of mucolytic and colitogenic bacteria.28 There-
fore, because IL-33 has been shown to be important for gut homeosta-
sis and in ameliorating intestinal inflammation, our study suggests that
the significant decrease in IL-33 expression in the duodenal mucosa of
GSDs with CE may cause or contribute to the chronic intestinal
inflammation seen in this disease. Interestingly, a previous study
documented increased NF-κB activity in dogs with CE.34 Because nuclear
IL-33 can sequester NF-κB, leading to decreased proinflammatory signal-
ing, decreased IL-33 mRNA expression in GSDs with CE may result in
increased NF-κB activation with a subsequent increase in inflammation.
However, additional studies would be needed to confirm this mechanism
for increased NF-κB activation in dogs with CE. Additionally, GSDs
with CE previously have been shown to have relatively decreased
IgA production, as well as intestinal dysbiosis.35,36 However, the
definitive mechanism for these findings is unknown. Our study
suggests that decreased intestinal IL-33 expression in GSDs with
CE might be associated with the previously documented decreased
intestinal IgA production and dysbiosis, similar to the findings
seen in IL-33 knockout mouse models.28 If IL-33 is determined to
play a role in the pathogenesis of CE in GSDs, exogenous IL-33
could be explored as a possible specific treatment option in this
breed. Therefore, further studies are warranted to investigate
the consequences of decreased IL-33 mRNA expression in GSDs
with CE, such as decreased IgA production and altered intestinal
microbiota.
Although the recent GWAS in GSDs with CE did not specifically
implicate possible polymorphisms in the IL-33 gene, it did implicate
other Th2 genes such as IL-13 that potentially contribute to the path-
ogenesis of tissue injury.13 Therefore, the expression of IL-33 may be
a consequence of altered expression of other Th2 cytokines in GSDs
with CE because of polymorphisms in these genes. However,
F IGURE 4 RNA in situ hybridization of interleukin (IL)-33 in the
duodenal mucosa of a German Shepherd dog with chronic
enteropathy (left images; top to bottom: villus, subvillus, epithelial,
and lamina propria) and a healthy Beagle control dog (right images;
top to bottom: villus, subvillus, epithelial, lamina propria, and negative
control)
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functional studies would be needed to definitively prove the role of
these implicated genes and their consequent effects on other Th2
cytokines in the pathogenesis of CE in GSDs.
Our study did not show a significant difference in duodenal IL-33
mRNA expression scores between non-GSDs with CE and healthy
dogs. This finding is in contrast to a previous study, which docu-
mented significantly decreased mRNA expression of IL-33 in the duo-
denum of dogs with food-responsive enteropathy (FRE) compared to
healthy Beagle dogs.37 The lack of significance in our study might be
because of the inclusion of different non-GSD breeds of dogs with
CE, whereas the previous study contained 7 dogs, each a different
non-GSD breed with FRE and only 1 of the dogs in our non-GSD
group was the same breed. In addition, our study did not sub-
categorize dogs with CE into treatment response, histological severity
or type of inflammatory infiltrate. Therefore, the heterogeneity of
breed, treatment response, and histopathologic severity and type of
cellular infiltrate of CE in our non-GSD group may have diluted any
significant effects from single breeds, FRE, or histologic type resulting
in nonsignificance. Therefore, future studies investigating the
etiopathogenesis of CE in dogs should focus on homogenous
populations using the same breeds, treatment response, and intestinal
histologic type.
Interleukin-13 is a Th2 cytokine that is produced mainly by T cells
and natural killer cells.38 It also has been shown to weaken epithelial
barrier function and induce epithelial cell apoptosis and downregulation
of tight junction proteins.39 However, studies have produced ambigu-
ous result with regard to its role in human and mouse models of IBD.
Some studies have documented large amounts of IL-13 in the intestinal
epithelium of patients with UC.40-43 Interleukin-13 has been suggested
to be a cause of inflammation, because UC patients treated with
interferon-beta-1a had significantly downregulated IL-13 production.44
However, other studies have documented significantly decreased IL-13
concentrations in patients with UC compared with controls, with
concentrations lower in active UC versus inactive UC.45,46 Some earlier
studies have described IL-13 as an anti-inflammatory agent in vitro,
because it inhibited monocyte secretion of IL-1 beta in a dose-dependent
manner.47 We determined that IL-13 mRNA was significantly decreased
in the duodenal mucosa of GSDs with CE compared with non-GSDs with
CE and healthy control dogs. A previous GWAS in GSDs with CE impli-
cated polymorphisms in the IL-13 gene.13 Therefore, our study sug-
gests that polymorphisms in the IL-13 gene in GSDs with CE may
result in decreased expression of this possible anti-inflammatory cyto-
kine, which may cause or contribute to the increased inflammation
seen in this disease. However, our study did not correlate mRNA
expression of IL-13 with the respective genotype in these dogs and
therefore this possibility cannot be confirmed. Therefore, additional
studies correlating IL-13 mRNA expression with genotype profiles are
warranted to confirm whether these polymorphisms have functional
impact. Exogenous IL-13 treatment then could be explored for CE in
this breed if the polymorphisms in the IL-13 gene are shown to result
in a loss of function.
Interestingly, our study showed that non-GSDs with CE had signif-
icantly increased IL-13 mRNA duodenal epithelial average expression
scores compared to healthy control dogs. This observation suggests
that in some non-GSD breeds with CE, IL-13 also may play a role in
disease pathogenesis. However, IL-13 likely plays a different role in
non-GSDs with CE because the expression was increased compared
to healthy dogs, whereas in GSDs with CE the expression was signifi-
cantly decreased in the duodenum. Therefore, cytokines may play dif-
ferent roles in the pathogenesis of CE depending on the breed,
perhaps because of the different genetic backgrounds, and conse-
quently future studies investigating different cytokines in dogs with
CE should focus on individual breeds.
In addition to the lack of genotype association with mRNA expres-
sion of IL-13, other limitations of our study included the use of partial
thickness endoscopic biopsy samples for RNA ISH rather than full-
thickness biopsy samples and therefore cells expressing IL-13 or IL-33
mRNA in the deeper layers would have been missed. Our study
assessed mRNA expression which provides no information on protein
expression or function, and may have been unaltered by the
decreased mRNA expression of IL-13 or IL-33. Also, because of finan-
cial constraints, semi-quantitative analysis was used to determine
expression of IL-13 and IL-33 mRNA rather than absolute quantifica-
tion. The non-GSD CE group was heterogeneous and contained only
1-2 dogs from the same breed and therefore any significant effects
from individual breeds would have been diluted. Our control group
contained exclusively healthy Beagle dogs that were from a research
colony and were relatively young and from a different country com-
pared to the dogs with CE. We are unable to rule out the effect of
these confounding factors on the expression of IL-13 and IL-33
mRNA in the duodenal mucosa of these dogs and whether they are
responsible for the differences seen compared to the dogs with
CE. Because our study contained small numbers in both the CE and
non-GSD CE groups, statistical correlations to disease activity,
WSAVA duodenal histopathology scores, or treatment response
could not be performed. Our study included only mRNA expression
in the duodenum and therefore expression in other locations in the
intestinal tract such as the colon or ileum may have been different.
Finally, additional Th2 cytokines for which polymorphisms have
been suggested in GSDs with CE, such as IL-4 and IL-5, were not
assessed and therefore may have provided additional insights into
the pathogenesis of this disease.
In conclusion, our study showed that GSDs with CE exhibited
decreased expression of IL-13 and IL-33 mRNA in the inflamed duo-
denal mucosa compared to non-GSDs with CE and healthy Beagle
dogs. Further studies are needed to determine the consequences of
this decreased expression, such as decreased intestinal IgA production
and intestinal dysbiosis, as well as to determine if decreased expres-
sion is the cause or an effect of CE in this breed.
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